Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Public ClinicalTrials.gov record NCT01855945. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Multi-center, Observer-Blind, Randomized, Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated Novel Swine Origin A/H3N2v Monovalent Subunit Influenza Virus Vaccine (H3N2c) in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to < 65 Years and Elderly ≥ 65 Years and Older.
Study identification
- NCT ID
- NCT01855945
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Novartis Vaccines
- Industry
- Enrollment
- 627 participants
Conditions and interventions
Conditions
Interventions
- Swine Influenza Biological
Biological
Eligibility (public fields only)
- Age range
- 3 Years to 92 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2013
- Primary completion
- Aug 31, 2014
- Completion
- Aug 31, 2014
- Last update posted
- Feb 16, 2016
2013 – 2014
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 51, Northern California Clinical Research Center | Redding | California | 96001 | — |
| 47, Benchmark Research | Sacramento | California | 95822 | — |
| 46, Johnson County Clinical Trials | Lenexa | Kansas | 66213 | — |
| 49, Heartland Research Associates, LLC | Wichita | Kansas | 67207 | — |
| 43, Central Kentucky Research Associates | Lexington | Kentucky | 40509 | — |
| 41, Benchmark Research | Metairie | Louisiana | 70006 | — |
| 44, Rochester Clinical Research Inc. | Rochester | New York | 14609 | — |
| 50, PMG Research of Raleigh | Raleight | North Carolina | 27609 | — |
| 45, Omega Medical Research | Warwick | Rhode Island | 02886 | — |
| 42, Research Acros | Dallas | Texas | 75234 | — |
| 48, "J. Lewis Research, Inc. | Salt Lake City | Utah | 84109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01855945, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 16, 2016 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01855945 live on ClinicalTrials.gov.